ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financi...( EXTON Pa. Feb. 27 /- ViroPharma I...),Health

EXTON, Pa., Feb. 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and twelve months ended December 31, 2007.

Key events since September 30, 2007 include:

Development:

-- European Orphan Drug Designation received for Camvia(TM) (maribavir);

-- Patient enrollment continued in both phase 3 studies of Camvia in stem

cell and solid organ transplant patients;

-- Prelaunch activities for Camvia accelerated including new medical

affairs and PR initiatives in preparation for the planned 2009 NDA and

MAA filings;

-- Monitoring and follow-up of patients who received HCV-796 in ongoing

phase 2 study continued; evaluation of potential benefits versus risks

to patients is ongoing to understand if and how further clinical

studies are appropriate; and

-- Work continued to optimize manufacturing and scale up for non-toxigenic

C. difficile (NTCD) project in preparation for human clinical trials.

Operational:

-- Net sales of Vancocin(R) were $48 million;

-- Launched new sales and marketing initiatives for Vancocin; and

-- Research and development expenses increased by 305 percent over the

fourth quarter of 2006, primarily driven by investments in Camvia, NTCD

and increased personnel to support clinical momentum.

Financial Results

-- Operating income was $19 million;

-- Increased working capital by $21 million to $594 million;

-- Cash, cash equivalents and short-term investments grew by $32 million

to $584 million; and

-- 12th consecutive quarter of positive cash flow and profitability'/>"/>